-
Application of JAK1 Inhibitors in Peripheral T-cell Lymphoma: Highlights from the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference
From March 23rd to 24th, 2024, the 15th Chinese Medical Association Hematology Academic Conference and the First Rare Blood Disease Academic Conference, hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, and co-organized by the First Affiliated Hospital of Soochow University, was successfully held in Suzhou, Jiangsu Province, China.…
-
SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed
Led by Professor Qiang Liu and Professor Yaping Yang from the Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital at Sun Yat-sen University, the final clinical study results of a new neoadjuvant treatment regimen for HER2-positive breast cancer were disclosed for the first time. The results were presented in the form of a POSTER at the…
-
SABCS Voice of China | Teams led by Professors Yuanting Gu and Jingruo Li Announce Results of CDK4/6 Inhibitor Combined with Letrozole as Neoadjuvant Treatment for Early or Locally Advanced HR+/HER2- Breast Cancer
The results of a single-arm, multicenter, prospective exploratory clinical study on the neoadjuvant treatment of HR-positive, HER2-negative (HR+/HER2-) breast cancer with Dalpiciclib combined with Letrozole, led by Professor Yuanting Gu and Professor Jingruo Li from the First Affiliated Hospital of Zhengzhou University, were selected for poster presentation at the 2023 SABCS conference. The unveiling of…
-
SABCS Voice of China丨Professor Jian Zhang: Orally Administered SERD That Can Cross the Blood-Brain Barrier Challenges the Dilemma of Endocrine Treatment for ER+/HER2- Advanced Breast Cancer
The 46th San Antonio Breast Cancer Symposium (SABCS), a prestigious academic event in the field of international breast cancer, was held from December 5th to 9th in San Antonio, Texas, USA. A Phase I clinical study of a new selective estrogen receptor degrader (SERD) led by Professor Jiong Wu and Professor Jian Zhang ‘s team…
-
EAU24 Interview | Dr. Matthew Galsky reports the OS results of the CheckMate 274 study for the first time, showing benefit trends from adjuvant immunotherapy
Dr. Matthew Galsky Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Oncology Frontier：In recent years, research in the field of urothelial cancer has continued to make breakthroughs. Could…
-
EAU24 Interview | Dr. Jianming Guo and Dr. Riccardo Campi Discuss Renal Cancer Surgical Treatments
Dr. Jianming Guo Zhongshan Hospital Fudan University, Dept. of Urology, Shanghai, China Dr. Riccardo Campi Careggi Hospital, University of Florence, Florence, Italy Oncology Frontier: Both of you have had research…
-
SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed
Led by Professor Qiang Liu and Professor Yaping Yang from the Sun Yat-sen Memorial Hospital’s Breast Tumor Hospital at Sun Yat-sen University, the final clinical study results of a new neoadjuvant treatment regimen for HER2-positive breast cancer were disclosed for the first time. The results were presented in the form of a POSTER at the…
-
SABCS Voice of China | Professor Jian Liu: A New Strategy for Treating HER2-Positive Advanced Breast Cancer in China
Currently, the combination of docetaxel, trastuzumab, and pertuzumab is the standard first-line treatment for HER2-positive metastatic breast cancer (MBC), but still, 60% of patients experience disease progression after 2 years of treatment. The second-line treatment standards include DS-8201, T-DM1, TKIs, etc., but these options still have their limitations and do not fully meet clinical treatment…
Connecting Medical Expertise through Media